Renal aspects of thalassaemia a changing paradigm

European Journal of Haematology

Volumn 89, Issue 3, 2012, Pages 187-197

  Bhandari, Sunil ^a   Galanello, Renzo ^b  

^a HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Chelators; Iron; Kidney; Oxidative stress; Thalassaemia; Tubule

Indexed keywords

CYSTATIN C; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; MALONALDEHYDE; VITAMIN D;

ACUTE KIDNEY FAILURE; AMINOACIDURIA; ANEMIA; BLOOD TRANSFUSION; CASE CONTROL STUDY; CELL FUNCTION; COMPARATIVE STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIARRHEA; DRUG MEGADOSE; ERYTHROPOIESIS; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION; HEAVY METAL POISONING; HEMATURIA; HEMOLYSIS; HEPATITIS B; HEPATITIS C; HUMAN; HYPERCALCIURIA; HYPERCHLOREMIC ACIDOSIS; HYPERURICOSURIA; HYPOXIA; INTERSTITIAL NEPHRITIS; IRON CHELATION; IRON OVERLOAD; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY TUBULE ACIDOSIS; KIDNEY VASCULAR RESISTANCE; MICROALBUMINURIA; NEPHROLITHIASIS; PHOSPHATURIA; PRIORITY JOURNAL; PROTEINURIA; PYURIA; RECURRENT INFECTION; REVIEW; SEPSIS; SICKLE CELL ANEMIA; SIDE EFFECT; THALASSEMIA; THALASSEMIA MAJOR; TUBULAR DYSFUNCTION; ULTRAFILTRATION; URIC ACID BLOOD LEVEL; URINARY EXCRETION; VOMITING;

BETA-THALASSEMIA; CHELATING AGENTS; GREAT BRITAIN; HUMANS; KIDNEY FAILURE, CHRONIC;

EID: 84865146001     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2012.01819.x     Document Type: Review

References (98)

1. Olivieri NF The beta-thalassemias. N Engl J Med 1999;341:99-109.
2. Forget B Hematology: Basic principles and practice. Chapter 41. New York: Churchill Livingstone, Thalassemia syndromes, 2000:485-525.
3. Rund D, Rachmilewitz E Beta-thalassemia. N Engl J Med 2005;353:1135-46.
4. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006;107:3733-7.
5. Berdoukas V, Chouliaras G, Moraitis P, Zannikos K, Berdoussi E, Ladis V The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study. J Cardiovasc Magn Reson 2009;11(Suppl 20):1-11.
6. Ladis V, Chouliaras G, Berdoukas V, Moraitis P, Zannikos K, Berdoussi E, Kattamis C Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit. Eur J Haematol, 2010;85:335-44.
7. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-47.
8. Richards N, Harris K, Whitfield M, O'Donoghue D, Lewis R, Mansell M, Thomas S, Townwnd J, Marcelli D Primary care-based disease management of chronic kidney disease (CKD), based on estimated glomerular filtration rate (eGFR) reporting, improves patient outcomes. Nephrol Dial Transplant 2008;23:549-55.
9. Richards N, Harris K, Whitfield M, O'Donoghue D, Lewis R, Mansell M, Thomas S, Townend J, Eames M, Marcelli D The impact of population-based identification of chronic kidney disease using estimated glomerular filtration rate (eGFR) reporting. Nephrol Dial Transplant 2008;23:556-61.
10. Cheung CK, Bhandari S Perspectives on eGFR reporting from the interface between primary and secondary care. Clin J Am Soc Nephrol 2009;4:258-60.
11. Cox HJ, Bhandari S, Rigby AS, Kilpatrick ES Mortality at low and high estimated glomerular filtration rate values: a 'U' shaped curve. Nephron Clin Pract 2008;110:c67-72.
12. Couser WG, Riella MC World Kidney Day 2011: protect your kidneys, save your heart. Med J Aust 2011;194:225-7.
13. Astor BC, Levey AS, Stevens LA, Van Lente F, Selvin E, Coresh J Method of glomerular filtration rate estimation affects prediction of mortality risk. J Am Soc Nephrol 2009;20:2214-22.
14. Papassotiriou I, Margeli A, Hantzi E, Delaporta P, Sergounioti A, Goussetis E, Ladis V, Kattamis A Cystatin C levels in patients with beta-thalassemia during deferasirox treatment. Blood Cells Mol Dis 2010;44:152-5.
15. Hallan SI, Ritz E, Lydersen S, Romundstad S, Kvenild K, Orth SR Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol 2009;20:1069-77.
16. Lambers Heerspink HJ, Gansevoort RT, Brenner BM, Cooper ME, Parving HH, Shahinfar S, de Zeeuw D Comparison of different measures of urinary protein excretion for prediction of renal events. J Am Soc Nephrol 2010;21:1355-60.
17. Di Iorio BR, Aucella F, Stallone C, Bellizzi V Thalassaemia minor: national survey of uraemic patients under substitutive treatment. G Ital Nefrol 2002;19:286-93.
18. Quinn CT, Johnson VL, Kim H-Y Renal dysfunction in patients with thalassaemia. Br J Haematol 2011;153:111-7.
19. Aldudak B, Karabay Bayazit A, Noyan A, Ozel A, Anarat A, Sasmaz I, Kilinc Y, Gali E, Anarat R, Dikmen N Renal function in pediatric patients with beta-thalassemia major. Pediatr Nephrol 2000;15:109-12.
20. Mastrangelo F, Lopez T, Rizzelli S, Manisco G, Corliano C, Alfonso L Function of the kidney in adult patients with Cooley's disease. A preliminary report. Nephron 1975;14:229-36.
21. Ali D, Mehran K, Moghaddam AG Comparative evaluation of renal findings in Beta-thalassemia major and intermedia. Saudi J Kidney Dis Transpl 2008;19:206-9.
22. Mohkam M, Shamsian BS, Gharib A, Nariman S, Arzanian MT Early markers of renal dysfunction in patients with beta-thalassemia major. Pediatr Nephrol 2008;23:971-6.
23. Smolkin V, Halevy R, Levin C, Mines M, Sakran W, Ilia K, Koren A Renal function in children with beta-thalassemia major and thalassemia intermedia. Pediatr Nephrol 2008;23:1847-51.
24. Koren G, Bentur Y, Strong D, Harvey E, Klein J, Baumal R, Spielberg SP, Freedman MH Acute changes in renal function associated with deferoxamine therapy. Am J Dis Child 1989;143:1077-80.
25. Koliakos G, Papachristou F, Koussi A, Perifanis V, Tsatra I, Souliou E, Athanasiou M Urine biochemical markers of early renal dysfunction are associated with iron overload in beta-thalassaemia. Clin Lab Haematol 2003;25:105-9.
26. Lapatsanis P, Sbyrakis S, Vertos C, Karaklis BA, Dosiadis S Phosphaturia in thalassemia. Pediatrics 1976;58:885-92.
27. Sumboonnanonda A, Malasit P, Tanphaichitr VS, Ong-ajyooth S, Sunthornchart S, Pattanakitsakul S, Petrarat S, Assateerawatt A, Vongjirad A Renal tubular function in beta-thalassemia. Pediatr Nephrol 1998;12:280-3.
28. Grossman H, Dische MR, Winchester PH, Canale V Renal enlargement in thalassemia major. Radiology 1971;100:645-8.
29. Harada T, Ozono Y, Myazaki M, Yamaguchi K, Kanamoto Y, Hara K, Taguchi T Association of IgA nephropathy and beta-thalassemia. Clin Nephrol 1994;41:181-2.
30. Shah SV, Baliga R, Fonseca VA, Rajapurkar M Oxidants in chronic kidney disease. J Am Soc Nephrol 2007;18:16-28.
31. Malik AB, Vamferdam R, Justus R, Ounpraseuth S Iron chelation with DFP for diabetic nephropathy in the db/db mouse. J Am Soc Nephrol 2011;21:710A, 2567. [Abstract].
32. Agarwal R Proinflammatory effects of iron sucrose in chronic kidney disease. Kidney Int 2006;69:1259-63.
33. Landing BH, Gonick HC, Nadorra RL, Hyman CB, Wells TR, Villarreal-Engelhardt G, Mersch J, Agness CL Renal lesions and clinical findings in thalassemia major and other chronic anemias with hemosiderosis. Pediatr Pathol 1989;9:479-500.
34. Zhou XJ, Laszik Z, Wang XQ, Silva FG, Vaziri ND Association of renal injury with increased oxygen free radical activity and altered nitric oxide metabolism in chronic experimental hemosiderosis. Lab Invest 2000;80:1905-14.
35. Sadeghi-Bojd S, Hashemi M, Karimi M Renal tubular function in patients with beta-thalassaemia major in Zahedan, southeast Iran. Singapore Med J 2008;49:410-2.
36. Jalali A, Khalilian H, Ahmadzadeh A, Sarvestani S, Rahim F, Zandian K, Asar S Renal function in transfusion-dependent pediatric beta-thalassemia major patients. Hematology 2011;16:249-54.
37. Halliwell B, Gutteridge JM Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol 1990;186:1-85.
38. Kassab-Chekir A, Laradi S, Ferchichi S, Haj Khelil A, Feki M, Amri F, Selmi H, Bejaoui M, Miled A Oxidant, antioxidant status and metabolic data in patients with beta-thalassemia. Clin Chim Acta 2003;338:79-86.
39. Baliga R, Ueda N, Walker PD, Shah SV Oxidant mechanisms in toxic acute renal failure. Drug Metab Rev 1999;31:971-97.
40. Ueda N, Mayeux PR, Baliga R, Shah SV Oxidant mechanisms in acute renal failure. In: Molitoris B, Finn W, eds. Acute Renal Failure: A Companion to Brenner & Rector's The Kidney. Philadelphia: W. B. Saunders Company; 2001: 60-77.
41. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network (AKIN): report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11:R31.
42. Agarwal R, Leehey DJ, Olsen SM, Dahl NV Proteinuria induced by parenteral iron in chronic kidney disease-a comparative randomized controlled trial. Clin J Am Soc Nephrol, 2011;6:114-21.
43. Rajapurkar M, Gang S, Hegde U, Gohel K, Shah SV Study of urinary catalytic (bleomycin-detectable) iron following radiocontrast exposure in healthy kidney donors. J Am Soc Nephrol 2007;18:575A.
44. Hanss BG, Valencia SH, Shah SV, Vari RC The iron chelator deferoxamine prevents contrast media induced acute renal failure in the rabbit. J Am Soc Nephrol 1990;1:612.
45. Schein A, Enriquez C, Coates TD, Wood JC Magnetic resonance detection of kidney iron deposition in sickle cell disease: a marker of chronic hemolysis. J Magn Reson Imaging 2008;28:698-704.
46. Maier-Redelsperger M, Levy P, Lionnet F, Stankovic K, Haymann J-P, Lefevre G, Avellino V, Perol JP, Girot R, Elion J Strong association between a new marker of hemolysis and glomerulopathy in sickle cell anemia. Blood Cells Mol Dis 2010;45:289-92.
47. Ferrari P, Kulkarni H, Dheda S, Betti S, Harrison C, St Pierre TG, Olynyk JK Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. Clin J Am Soc Nephrol 2011;6:77-83.
48. Nagababu E, Gulyani S, Earley CJ, Cutler RG, Mattson MP, Rifkind JM Iron-deficiency anaemia enhances red blood cell oxidative stress. Free Radical Res 2008;42:824-9.
49. Kaissling B, Piess S, Rinne B, Le Hir M Effects of anemia on morphology of rat renal cortex. Am J Physiol 1993;264(4 Pt 2):F608-17.
50. Olivieri NF, Brittenham GM Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89(Suppl 3):739-61.
51. Brittenham GM, Nathan DG, Olivieri NF, Pippard MJ, Weatherall DJ Deferiprone versus desferrioxamine in thalassaemia, and T2*validation and utility. Lancet 2003;361:183; author reply 183-4.
52. Hoffbrand AV, Al-Refaie F, Davis B, Siritanakatkul N, Jackson BF, Cochrane J, Prescott E, Wonke B Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998;91:295-300.
53. Cappellini MD, Cohen A, Piga A, et al. Phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassaemia. Blood 2006;107:3455-62.
54. Rafat C, Ribeil JA Fanconi Syndrome due to deferasirox. Am J Kidney Dis 2009;54:931-4.
55. Yacobovich J, Stark P, Barzilai-Birenbaum S, Krause I, Pazgal I, Yaniv I, Tamary H Acquired proximal renal tubular dysfunction in -thalassemia patients treated with deferasirox. J Pediatr Hematol Oncol 2010;32:564-7.
56. Batey R, Scott J, Jain S, Sherlock S Acute renal insufficiency occurring during intravenous desferrioxamine therapy. Scand J Haematol 1979;22:277-9.
57. Cianciulli P, Sollecito D, Sorrentino F, Forte L, Palombi M, Papa G, Meloni C, Taccone GM, Casciani CU Early detection of nephrotoxic effects in thalassemic patients receiving desferrioxamine therap. Kidney Int 1994;396:467-70.
58. Cianciulli P, Sorrentino F, Forte L, Palombi M, Papa G, Meloni C, Taccone GM, Casciani CU Acute renal failure occurring during intravenous desferrioxamine therapy: recovery after haemodialysis. Haematologica 1992;77:514-5.
59. Li Volti S, Di Gregorio F, Schiliro G Acute changes in renal function associated with deferoxamine therapy. Am J Dis Child 1990;144:1069-70.
60. Li Volti S, Maccarone C, Li Volti G, Romeo MA Acute renal failure following deferoxamine overdose. Pediatr Nephrol 2003;18:1078-9.
61. Prasannan L, Flynn JT, Levine JE Acute renal failure following deferoxamine overdose. Pediatr Nephrol 2003;18:283-5.
62. Brosnahan G, Gokden N, Swaminathan S Acute interstitial nephritis due to deferasirox: a case report. Nephrol Dial Transplant 2008;23:3356-8.
63. Clajus C, Becker JU, Stichtenoth DO, Wortmann J, Schwarz A, Kielstein JT Acute kidney injury due to deferoxamine in a renal transplant patient. Nephrol Dial Transplant 2008;23:1061-4.
64. Cappellini MD, Porter J, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica 2010;95:557-66.
65. Adamkiewicz TV, Erkovitch M, Krishnan C, Polsinelli C, Kermack D, Olivieri NF Infection due to Yersinia enterocolitica in a series of patients with beta-thalassemia: incidence and predisposing factors. Clin Infect Dis 1998;27:1362-6.
66. Chan GC-F, Chan S, Ho P-L, Ha S-Y Effects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of Klebsiella pneumoniae and Aeromonas hydrophila isolated from transfusion-dependent thalassemia patients. Hemoglobin 2009;33:352-60.
67. Robins-Browne RM, Prpic JK Effects of iron and desferrioxamine on infections with Yersinia enterocolitica Infect Immun 1985;47:774-9.
68. Bhandari S Risk factors and metabolic mechanisms in the pathogenesis of uraemic cardiac disease. Front Biosci 2011;16:1364-87.
69. Aydinok Y, Unal S, Oymak Y, Vergin C, Türker ZD, Yildiz D, Yesilipek A Observational study comparing long-term safety and efficacy of Deferasirox with Desferrioxamine therapy in chelation-naïve children with transfusional iron overload. Eur J Haematol 2012;88:431-438.
70. Bhandari S, Daar SF, Panjwani VK Natural history of iron chelation toxicity in patients with thalassaemia major and intermedia in Oman. J Am Soc Nephrol 2011;22:870A, 2349. [Abstract].
71. Galanello R Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective. Ther Clin Risk Manag 2007;3:795-805.
72. El Alfy M, Sari TT, Lee CL, Tricta F, El-Beshlawy A The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload. J Pediatr Hematol Oncol 2010;32:601-5.
73. Papadopoulos N, Vasiliki A, Aloizos G, Tapinis P, Kikilas A Hyperchloremic metabolic acidosis due to deferasirox in a patient with beta thalassemia major. Ann Pharmacother 2010;44:219-21.
74. Kontoghiorghes GJ Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities. Expert Opin Drug Saf 2010;9:633-41.
75. Vlachaki E, Chatzinikolaou BE, Klonizakis F, Tsapas A Is deferasirox implicated in multiple organ failure in a patient with homozygous β-thalassemia? Angiology 2011;62:346-8.
76. Rheault MN, Bechtel H, Neglia JP, Kashtan CE Reversible Fanconi syndrome in a pediatric patient on deferasirox. Pediatr Blood Cancer 2011;56:674-6.
77. Chandra J, Chaudhary H, Pemde H, Singh V, Dutta AK Safety and efficacy of deferasirox in multitransfused Indian children with -thalassaemia major. Ann Trop Paediatr 2011;31:47-51.
78. Huang X-P, Thiessen JJ, Spino M, Templeton DM Transport of iron chelators and chelates across MDCK cell monolayers: implications for iron excretion during chelation therapy. Int J Hematol 2010;91:401-12.
79. Taher A, Cappellini MD, Vichinsky E, Galanello R, Piga A, Lawniczek T, Clark J, Habr D, Porter JB Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol 2009;147:752-9.
80. Taher A, Elalfy MS, Al Zir K, Daar S, Al Jefri A, Habr D, Kriemler-Krahn U, El-Ali A, Roubert B, El-Beshlawy A Importance of optimal dosing ≥30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia. Eur J Haematol 2011;87:355-65.
81. Cappellini MD, Bejaoui M, Agaoglu L, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood 2011;118:884-93.
82. Cappellini MD, Taher A Deferasirox (Exjade) for the treatment of iron overload. Acta Haematol 2009;122:165-73.
83. Piga A, Galanello R, Forni GL, et al. Andomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006;91:873-80.
84. Bergeron R, Treilf R, Wingand J, Vinson J A comparative evaluation of iron clearance models. Ann N Y Acad Sci 1990;6:378-93.
85. Tanji K, Imaizumi T, Matsumiya T, et al. Desferrioxamine, an iron chelator, upregulates cyclooxygenase-2 expression and prostaglandin production in a human macrophage cell line. Biochim Biophys Acta 2001;1530:227-35.
86. Piga A Renal Blood flow in deferasirox therapy. TIFF, 2011. abstract op03.
87. Holtkamp FA, e Zeeuw D, Thomas MC, Cooper ME, de Graeff PA, Hillege HJL, Parving HH, Brenner BM, Shahinfar S, Lambers HHJ An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int, 2011;80:282-7.
88. Sanchez-Gonzalez P, Lopez-Hernandez F, Morales AI, Macías-Nuñez JF, López-Novoa JM Effects of deferasirox on renal function and renal epithelial cell death. Toxicol Lett 2011;203:154-61.
89. Zager RA, Johnson AM, Hanson SY, Wasse H Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 2002;40:90-103.
90. Gao X, Qian M, Campian JL, Marshall J, Zhou Z, Roberts AM, Kang YJ, Prabhu SD, Sun XF, Eaton JW Mitochondrial dysfunction may explain the cardiomyopathy of chronic iron overload. Free Radical Biol Med 2010;49:401-7.
91. Rao M, Li L, Demello C, Guo D, Jaber BL, Pereira BJG, Balakrishnan VS, on behalf of the HEMO study Group. Mitochondrial DNA injury and mortality in hemodialysis patients. J Am Soc Nephrol 2009;20:189-96.
92. Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375:2073-81.
93. Ninomiya T, Perkovic V, de Galan BE, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009;20:1813-21.
94. Brittenham GM Iron-chelating therapy for transfusional iron overload. N Engl J Med 2011;364:146-56.
95. Farmaki K, Angelopoulos N, Anagnostopoulos G, Gotsis E, Rombopoulos G, Tolis G Effect of enhanced iron chelation therapy on glucose metabolism in patients with β-thalassaemia major. Br J Haematol 2006;134:438-44.
96. Farmaki K, Tzoumari I, Pappa C Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications. Blood Cells Mol Dis 2011;47:33-40.
97. Alpendurada F, Smith G, Carpenter JP, Nair S, Tanner M, Banya W, Dessi C, Galanllo R, Walker J, Pennell D, Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major. J Cardiovasc Magn Reson 2012;14:8.
98. Balocco M, Carrara P, Pinto V, Forni GL Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" β-thalassemia major patients. Am J Hematol 2010;85:460-1.